The relevance of the hematopoietic niche for therapy resistance in acute myeloid leukemia
International Journal of Cancer · 2024
DOI: 10.1002/ijc.34684 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Catana Allert und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany. Hauptthemen laut MEDLINE: Hematopoietic Stem Cells, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, José Carreras Leukämie-Stiftung.
Abstract (Originalsprache)
The expansion of acute myeloid leukemia (AML) blasts not only suppresses normal hematopoiesis, but also alters the microenvironment. The interplay of different components of the bone marrow gives rise to altered metabolic states and activates signaling pathways which lead to resistance and impede effective therapy. Therefore, the underlying processes and mechanisms represent attractive therapeutic leverage points for overcoming therapy resistance in AML. Here, we briefly discuss resistance mechanisms based on cell interactions and secreted soluble factors in the hematopoietic niche and provide an overview of niche‐related therapeutic targets currently undergoing preclinical and clinical investigation which may help improve the outcome in AML therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
- University of Heidelberg Medical Faculty, Heidelberg, Germany.
- Molecular Medicine Partnership Unit (MMPU), University of Heidelberg and European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
- Division Proteomics of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
ORCID-Profile: Maximilian Felix Blank
Förderung
- Deutsche Forschungsgemeinschaft
- Deutsche Krebshilfe
- José Carreras Leukämie-Stiftung
- Wilhelm-Sander-Stiftung
Zitieren
APA
Allert, C., Müller-Tidow, C., & Blank, M. F. (2024). The relevance of the hematopoietic niche for therapy resistance in acute myeloid leukemia. International Journal of Cancer. https://doi.org/10.1002/ijc.34684
Vancouver
Allert C, Müller-Tidow C, Blank MF. The relevance of the hematopoietic niche for therapy resistance in acute myeloid leukemia. International Journal of Cancer. 2024. doi:10.1002/ijc.34684
BibTeX
@article{Allert2024,
author = {Allert, Catana and Müller-Tidow, Carsten and Blank, Maximilian Felix},
title = {The relevance of the hematopoietic niche for therapy resistance in acute myeloid leukemia},
journal = {International Journal of Cancer},
year = {2024},
doi = {10.1002/ijc.34684}
}
EUVIMED